Mammalian Polyclonal IgG Antibody Market Size, Share & Trends Analysis Report By Type (Mouse, Rabbit), By Product (Cardiac, Metabolic), By Application (Western Blotting, ELISA), By End-user- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The global mammalian polyclonal IgG antibody market size was exhibited at USD 2.90 billion in 2022 and is projected to hit around USD 4.81 billion by 2032, growing at a CAGR of 5.2% during the forecast period 2023 to 2032.

Key Pointers:

• North America dominated the industry in 2022 and accounted for the maximum share of 40.99% of the overall revenue
• Asia Pacific is anticipated to witness the fastest CAGR during the forecast period
• The mouse segment is expected to generate significant revenue by 2032.
• The mouse segment is anticipated to exhibit the fastest CAGR of 8.61% from 2023 to 2032 
• The metabolic biomarkers segment dominated the industry in 2022 and accounted for the largest share of 25.9% of the overall revenue.
• The ELISA segment is anticipated to register the highest CAGR of 7.49% over the forecast years 
• The other hand, the western blotting segment held the highest revenue share in 2022 .
• The pharmaceutical and biotech companies segment is the major contributor to the industry and accounted for the maximum share of more than 34.15% of the overall revenue in 2022. 
• The diagnostic centers segment is anticipated to exhibit the highest CAGR during the forecast period. 

Mammalian Polyclonal IgG Antibody Market Report Scope

The industry has witnessed significant growth owing to the development of innovative drugs and increasing government initiatives. Pharma and biotech companies are indulging in rigorous research and development since the antibody-drug conjugate is considered to be the fastest-growing field of the pharmaceutical market.In October 2022, SAB Biotherapeutics announced an exclusive partnership with Emergent BioSolutions Inc. According to the agreement, Emergent BioSolutions is expected to offer end-to-end services of Contract Development and Manufacturing (CDMO) to produce polyclonal antibody-based products.

The partnership will enable SAB Biotherapeutics to primarily focus on the research and development of the polyclonal antibody drug pipeline. As of October 2022, the company is conducting various clinical-stage programs in the treatment of influenza, acute and recurrent C. diff., Type 1 diabetes and researching potential candidates in oncology and immunology. The COVID-19 pandemic surged the use of polyclonal antibodies across the globe. For instance, in July 2022, GigaGen Inc. announced the publication of research showcasing its studies of GIGA-2050, recombinant polyclonal antibodies for COVID-19. According to the research, the GIGA-2050 has an effective manufacturing approach to treating infectious diseases by targeting numerous viral epitopes.

The company has leveraged its existing technology to develop medicines for infectious diseases. Key companies are continuously expanding their product and service portfolios to accelerate the development and manufacturing of the product. For instance, in October 2022, Amerigo Scientific, a distributor, introduced its recent development of polyclonal antibodies to human blood coagulation factor XIII to assist professionals in the area of life science for detecting blood coagulation factor XIII. However, the product is solely for research purposes and not for therapeutic or diagnostics. The development of this product is expected to strengthen the company’s position in biomedical research applications.

Mammalian Polyclonal IgG Antibody Market Segmentation